RNA Nanotherapeutics Develops Novel Approach to Combat Tamoxifen Resistance in Breast Cancer
核心洞察
University of Cincinnati startup RNA Nanotherapeutics (搜索) has developed multifunctional RNA nanoparticles that precisely target MED1 (搜索) protein to overcome tamoxifen resistance in breast cancer (搜索) patients.
Preclinical studies demonstrate superior tumor-specific targeting and efficacy compared to current treatments, with no toxicity observed even at 10 times the effective dose.
The company aims to advance its breast cancer (搜索) therapy into clinical trials within five years and has secured multiple funding awards including Ohio's Third Frontier TVSF Phase 2 award.
University of Cincinnati professor Xiaoting Zhang has launched RNA Nanotherapeutics (搜索), a startup developing innovative RNA nanotechnology to address tamoxifen resistance in breast cancer (搜索) patients. The company's approach targets MED1 (搜索), a protein that enables cancer cells to ignore tamoxifen treatments and reduces patient survival rates.
Targeting Treatment Resistance
Zhang's research focuses on overcoming a critical challenge in breast cancer (搜索) treatment: drug resistance. According to the American Cancer Society's 2025 findings, one in eight American women will face a breast cancer diagnosis in their lifetime, yet standard treatments aren't always effective. The estrogen receptor (搜索) is present in 70%-75% of human breast cancers, making tamoxifen a cornerstone therapy that prevents estrogen from fueling cancer growth.
However, tamoxifen quickly loses its efficacy as cancer cells develop resistance. Zhang identified MED1 (搜索) as a key protein that helps breast cancer (搜索) cells ignore tamoxifen treatments, significantly lowering patients' likelihood of survival. Scientific evidence supports this theory, showing that MED1 levels are abnormally high in 40%-60% of breast cancers, with excessive amounts associated with adverse treatment outcomes.
RNA Nanoparticle Innovation
Zhang and his team have developed a process to deliver multifunctional RNA nanoparticles into cancer cells to precisely target MED1 (搜索). The approach works by blocking MED1 production, which prevents HER2 (搜索) and other signaling pathways from creating tamoxifen-resistant cells. This mechanism allows current medicines like tamoxifen to better eliminate cancer cells while boosting patient outcomes and survival rates.
The startup has successfully completed lead optimization, scaled up manufacturing, and conducted safety and efficacy testing across multiple preclinical models. Results demonstrate highly favorable tumor-specific targeting and superior efficacy compared to current medicines with fewer treatments required. Notably, the treatment showed no toxicity or harmful immune responses even at 10 times the effective dose.
Commercial Development and Funding
RNA Nanotherapeutics (搜索) has leveraged resources from UC's 1819 Innovation Hub, including the Venture Lab startup accelerator and Technology Transfer office. Zhang credits these programs with providing "both the foundational knowledge and the confidence needed to take our first steps as a company" and playing "a pivotal role in protecting and advancing our intellectual property."
The company has secured significant funding and recognition, completing validation studies through Ohio's Technology Validation and Startup Fund (TVSF) Phase I award, along with investments from the state's Entrepreneurial Services Provider program and the National Cancer Institute's Small Business Technology Transfer grant. RNA Nanotherapeutics (搜索) recently achieved another milestone by earning Ohio's Third Frontier TVSF Phase 2 award to accelerate commercialization efforts.
Future Clinical Development
Zhang envisions advancing the breast cancer (搜索) therapy into clinical trials within five years while seeking additional funding and strategic partnerships with pharmaceutical companies. The startup is "striving to secure the funding and investment required and establish strategic partnerships with big pharmaceutical companies and other stakeholders."
The company has received multiple honors, including recognition as an Investor Initiatives Program showcase company by the National Cancer Institute, selection as one of the 10 Best of the BioMidwest by SmartHealth Catalyzer, and finalist status for the Healthcare Heroes Award by the Cincinnati Business Courier.
Zhang remains optimistic about the potential impact: "If RNA Nanotherapeutics (搜索) accomplishes its goal, it means our patients will have access to a new class of safer and more effective treatments right through the existing pharmaceutical channels and medical practices. We expect to improve both the treatment outcome and quality of life at the same time for our patients and their families."